ERBB2 and gastric cancer: HER-Vaxx, combined with chemotherapy, enhances OS and PFS in HER2-positive GC patients by inducing HER2-specific antibodies, promoting ADCC, and reducing FOXP3+ Tregs, offering a safe alternative to trastuzumab in cases of intolerable toxicity (98).